- Home
- ZTR vs IGMS Comparison
ZTR vs IGMS Comparison
Compare ZTR & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTR
- IGMS
- Stock Information
- Founded
- ZTR 1988
- IGMS 1993
- Country
- ZTR Australia
- IGMS United States
- Employees
- ZTR N/A
- IGMS N/A
- Industry
- ZTR Investment Managers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ZTR Finance
- IGMS Health Care
- Exchange
- ZTR Nasdaq
- IGMS Nasdaq
- Market Cap
- ZTR 368.5M
- IGMS 348.5M
- IPO Year
- ZTR N/A
- IGMS 2019
- Fundamental
- Price
- ZTR $5.97
- IGMS $1.54
- Analyst Decision
- ZTR
- IGMS Hold
- Analyst Count
- ZTR 0
- IGMS 8
- Target Price
- ZTR N/A
- IGMS $6.14
- AVG Volume (30 Days)
- ZTR 219.4K
- IGMS 910.9K
- Earning Date
- ZTR 01-01-0001
- IGMS 03-06-2025
- Dividend Yield
- ZTR 12.09%
- IGMS N/A
- EPS Growth
- ZTR N/A
- IGMS N/A
- EPS
- ZTR N/A
- IGMS N/A
- Revenue
- ZTR N/A
- IGMS $2,918,000.00
- Revenue This Year
- ZTR N/A
- IGMS $26.85
- Revenue Next Year
- ZTR N/A
- IGMS $125.17
- P/E Ratio
- ZTR N/A
- IGMS N/A
- Revenue Growth
- ZTR N/A
- IGMS 57.64
- 52 Week Low
- ZTR $4.50
- IGMS $1.37
- 52 Week High
- ZTR $6.60
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ZTR 53.97
- IGMS 19.44
- Support Level
- ZTR $5.91
- IGMS $1.37
- Resistance Level
- ZTR $6.02
- IGMS $1.59
- Average True Range (ATR)
- ZTR 0.07
- IGMS 0.16
- MACD
- ZTR 0.01
- IGMS 0.19
- Stochastic Oscillator
- ZTR 73.53
- IGMS 11.67
About ZTR Virtus Total Return Fund Inc.
Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective is capital appreciation, with current income as a secondary objective through a balance of equity and fixed income investments. It invests in operators of infrastructure in the communications, utility, energy, and transportation industries.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.